Next Generation Sequencers Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Next-generation sequencers are instruments used to determine the nucleotide sequence of DNA or RNA rapidly and efficiently. Offering an efficient throughput per sequencing, next-generation sequencers are capable of massively parallel processing and are instrumental in uncovering genetic variations, understanding complex diseases, and advancing research in areas such as cancer genomics, microbiology, and evolutionary biology.
The next-generation sequencers track the essential equipment only, and not accessories and/or additional costs associated with next-generation sequencer installation.
It is now standard to test for a high number of mutations to personalize treatment decisions, use of Next Generation Sequencers that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with installed base. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insights offer context for quantitative data.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Illumina Inc, Pacific Biosciences, Thermo Fisher Scientific Inc, Singular Genomics System Inc, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Next-generation sequencers are instruments used to determine the nucleotide sequence of DNA or RNA rapidly and efficiently. Offering an efficient throughput per sequencing, next-generation sequencers are capable of massively parallel processing and are instrumental in uncovering genetic variations, understanding complex diseases, and advancing research in areas such as cancer genomics, microbiology, and evolutionary biology.
The next-generation sequencers track the essential equipment only, and not accessories and/or additional costs associated with next-generation sequencer installation.
It is now standard to test for a high number of mutations to personalize treatment decisions, use of Next Generation Sequencers that can evaluate tumor biopsies for a wide range of potentially targetable mutations is increasing.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with installed base. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insights offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Next Generation Sequencers and evolving competitive landscape:
- Insightful review of the key industry trends.
- Annualized total Next Generation Sequencers market revenue by segment and market outlooks from
- Market level data on units, average selling prices and market values.
Global, Regional and Country level market specific insights:
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition, The analyst analysts provide unique country specific insights on the market.
- SWOT analysis for Next Generation Sequencers market.
- Competitive dynamics insights and trends provided for Next Generation Sequencers market.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Illumina Inc, Pacific Biosciences, Thermo Fisher Scientific Inc, Singular Genomics System Inc, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for :- CMO executives who must have deep understanding of the Next Generation Sequencers market place to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to :
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
- Develop business strategies by understanding the trends shaping and driving Next Generation Sequencers market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencers market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific Next Generation Sequencers market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Illumina Inc
- Pacific Biosciences
- Thermo Fisher Scientific Inc
- Singular Genomics System Inc